EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy

Zahraa Siddiqui, Serena Neumann, Daniel Guillen, Ruchee Patel, Rachel Cox, W Bryan Burnette, Rachel Harris, Saeed Mohammad, Jonathan H Soslow iD

Human Gene Therapy · 01.12.2026 · 37 (23-24) · 1158-1166

DOI: 10.1177/10430342261472609 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Human Gene Therapy, online erschienen am 05.08.2026. Verfasst von Zahraa Siddiqui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Sirolimus, Muscular Dystrophy, Duchenne, Genetic Therapy, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delandistrogene moxeparvovec-rokl (DMR) is the only U.S. Food and Drug Administration-approved gene therapy for patients with Duchenne muscular dystrophy (DMD). After reports of two deaths due to acute liver injury (ALI)/acute liver failure, our center began prophylaxis with sirolimus to help prevent ALI. The objective of this study is to report the initial safety, tolerability, and efficacy of sirolimus prophylaxis. The clinical course of patients receiving sirolimus prophylaxis with a target trough of 4–6 ng/mL was retrospectively evaluated and compared with those who did not receive sirolimus. Laboratory testing, particularly gamma glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, and total bilirubin, was collected. A Fisher’s exact test was used to assess the difference between groups. Twelve patients were started on sirolimus prophylaxis, 10 prior to DMR infusion and 2 within 2 weeks of DMR. The median age at DMR dosing was 11 years old (interquartile range = 8.5–14); 11 patients were ambulatory. No patients experienced a serious adverse event related to sirolimus administration. Seven patients developed elevated triglyceride or cholesterol levels and began omega-3 supplementation. None of the patients receiving sirolimus prophylaxis experienced ALI compared with 3 of the 14 patients (21%) infused prior to implementation of the sirolimus protocol. Sirolimus prophylaxis appears to be safe and well-tolerated in DMD patients receiving DMR. While not statistically significant, these results suggest that further study of sirolimus prophylaxis is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusMuscular Dystrophy, DuchenneGenetic TherapyRecombinant Fusion ProteinsHumansGene Therapy AgentsChildAdolescentMaleGenetic VectorsTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

Duchenne muscular dystrophyacute liver injurydelandistrogene moxeparvovec-roklgene therapysirolimus

Substanzen

SirolimusRecombinant Fusion Proteinsonasemnogene abeparvovecdelandistrogene moxeparvovec

Autor:innen und Institutionen

  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Division of Pediatric Neurology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pediatrics, Nemours Children's Health, Jacksonville, Florida, USA.
  • Division of Pediatric Gastroenterology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Jonathan H Soslow

Förderung

  • National Center for Advancing Translational Sciences

Zitieren

APA

Siddiqui, Z., Neumann, S., Guillen, D., Patel, R., Cox, R., Burnette, W. B., Harris, R., Mohammad, S., & Soslow, J. H. (2026). Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy. Human Gene Therapy, 37(23-24), 1158-1166. https://doi.org/10.1177/10430342261472609

Vancouver

Siddiqui Z, Neumann S, Guillen D, Patel R, Cox R, Burnette WB, et al. Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy. Human Gene Therapy. 2026;37(23-24):1158-1166. doi:10.1177/10430342261472609

BibTeX
@article{Siddiqui2026,
  author = {Siddiqui, Zahraa and Neumann, Serena and Guillen, Daniel and Patel, Ruchee and Cox, Rachel and Burnette, W Bryan and Harris, Rachel and Mohammad, Saeed and Soslow, Jonathan H},
  title = {Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy},
  journal = {Human Gene Therapy},
  year = {2026},
  volume = {37},
  number = {23-24},
  pages = {1158--1166},
  doi = {10.1177/10430342261472609}
}
Kostenlos starten →